# Megakaryon Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/megakaryon

- Industry: Biotechnology
- Headquarters: Kyoto-shi, Japan
- Website: www.megakaryon.com
- Total disclosed funding: $91M
- Latest round: Series D (Feb 17, 2020)
- Investors on record: 22

## About

Based in Kyoto, Japan, Megakaryon Corporation develops innovative human platelet products derived from induced pluripotent stem cells, enhancing transfusion safety and reliability for medical applications.Megakaryon Corporation, founded in 2011, specializes in producing human platelet products from induced pluripotent stem cells. Its notable development was the MEG-002 product, which aligns with patent advancements by Nakauchi-Eto. The company has executed a total of 5 deals, with the most recent funding round, Series D, occurring on December 21, 2023, raising JPY 2,800 mn from investors including INCJ and SBI Investment. As of this funding, Megakaryon’s total amount raised stands at JPY 2,800 mn with a current valuation of JPY 18,672.059 mn.Megakaryon Corporation specializes in the production of human platelet products derived from induced pluripotent stem cells (iPS cells). The company's flagship offering, the MEG-002 product, is a genetically matched human platelet formulation that aims to provide a safe, reliable source for transfusions, addressing critical shortages in blood supply. This innovation leverages the groundbreaking Nakauchi-Eto patent, which facilitates the stable and large-scale production of platelets. The primary end users of these products include hospitals, blood banks, and medical facilities looking to enhance their transfusion capabilities, particularly in regions experiencing high demand for platelet therapies. Currently, Megakaryon is focused on expanding its market reach within Japan, while also exploring opportunities in other global healthcare markets.Megakaryon Corporation generates revenue through its specialized products and services related to the manufacture and distribution of iPS cell-derived platelets. Business transactions are structured primarily on a B2B model, where hospitals and healthcare providers engage with the company to procure platelet products, potentially under long-term supply agreements or contracts for clinical trials. The pricing structure for these products is designed to reflect the quality and innovation associated with the MEG-002 offering, though specific pricing details are not publicly disclosed. By collaborating with medical institutions for clinical applications and research, Megakaryon aims to establish a sustainable revenue stream while simultaneously contributing to advancements in regenerative medicine and transfusion practices.Megakaryon Corporation plans to utilize the recent funding raised on December 21, 2023, to develop an automated manufacturing system for platelet preparations. The company aims to enhance efficiency in product manufacturing, enabling them to meet increasing market demands. Additionally, Megakaryon is exploring opportunities to expand its footprint beyond Japan to other global markets, although specific regions have yet to be defined. The company anticipates that these strategic initiatives will align with their goal of broadening access to their innovative platelet products.

## Funding rounds

- Series D, Feb 17, 2020, $26M — Sekisui Chemical, INCJ, SBI Investment, Satake Chemical Equipment Mfg.,Ltd.
- Series C, Dec 25, 2017, $33M — INCJ, Otsuka Pharmaceutical Co., Ltd., Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital, Miyako Capital, Shiga Bank, CMIC Holdings Co., Ltd., Sysmex, SBI Shinsei Corporate Investment, Shigagin Lease, Otsuka Pharmaceutical Factory, Inc., Kyoto Seisakusho Co., Ltd., SATAKE MultiMix Corporation, REVIC Capital Co., Ltd.
- Series B, Mar 25, 2015, $21M — Japan Asia Investment Company, INCJ, Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital, Nissay Capital, Miyako Capital, DBJ Capital, KSP
- Series A, Aug 26, 2013, $12M — INCJ, Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital

## Investors

- INCJ — Series A, Series B, Series C, Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B, Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series B, Series C
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A, Series B, Series C
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B
- Miyako Capital (https://capitalatlas.ai/funds/miyako-capital) — Series B, Series C
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series B
- KSP (https://capitalatlas.ai/funds/ksp) — Series B
- Otsuka Pharmaceutical Co., Ltd. — Series C
- Shiga Bank — Series C
- CMIC Holdings Co., Ltd. — Series C
- Sysmex — Series C
- SBI Shinsei Corporate Investment (https://capitalatlas.ai/funds/sbi-shinsei-corporate-investment) — Series C
- Shigagin Lease (https://capitalatlas.ai/funds/shigagin-lease) — Series C
- Otsuka Pharmaceutical Factory, Inc. — Series C
- Kyoto Seisakusho Co., Ltd. — Series C
- SATAKE MultiMix Corporation — Series C
- REVIC Capital Co., Ltd. — Series C
- Sekisui Chemical — Series D
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series D
- Satake Chemical Equipment Mfg.,Ltd. — Series D